Place of acetylsalicylic acid in updated recommendations for the prevention of cardiovascular events


DOI: https://dx.doi.org/10.18565/therapy.2020.8.123-134

Hadzegova A.B.

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow
Article contains an overview of Russian and foreign publications concerning the estimation of low-dose acetylsalicylic acid (ASA) efficacy in the secondary prevention of cardiovascular events. The history of the discovery of this medicine, the mechanisms of action and the place of low-dose ASA in the updated recommendations for acute coronary syndrome, stable coronary heart disease, ischemic stroke, transient ischemic attack, and peripheral arterial disease are presented.
Keywords: peripheral arterial disease, stable ischemic heart disease, acetylsalicylic acid, acute coronary syndrome, secondary prevention, transient ischemic attack, ischemic stroke
Read entire article

Literature


  1. Панченко Е.П., Явелов И.С., Грацианский Н.А. с соавт. Антитромботическая терапия у больных со стабильными проявлениями атеротромбоза. Кардиоваскулярная терапия и профилактика. 2009; 6 S6: 163–188. [Panchenko E.P., Yavelov I.S., Gratsiansky N.A. et al. Antithrombotic therapy in patients with stable manifestations of atherothrombosis. Kardiovaskulyarnaya terapiya i profrlaktika. 2009; 6 S6: 163–188 (In Russ.)].

  2. Garcia-Ropero A., Vargas-Delgado A.P., Santos-Gallego C.G., Badimon J.J. Direct oral anticoagulants and coronary artery disease: The debacle of the aspirin era? J Cardiovasc Pharmacol. 2020; 75(4): 269–75. doi: 10.1097/FJC.0000000000000795.

  3. Patrono C., Garcia Rodriguez L.A., Landolfi R. et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353(22): 2373–83. doi: 10.1056/NEJMra052717.

  4. Рафальский В.В., Крикова А.В., Павлюченкова Н.А. Низкодозовый аспирин: разнообразие лекарственных форм. Кардиоваскулярная терапия и профилактика, 2017; 4: 68–75. [Rafalsky V.V., Krikova A.V., Pavlyuchenkova N.A. Low dosage acetylsalicylic acid: a variety of formulations. Kardiovaskulyarnaya terapiya i profrlaktika. 2017; 4: 68–75 (In Russ.)]. doi: http://dx.doi.org/10.15829/1728-8800-2017-4-68-75.

  5. Serebruany V.L., Steinhubl S.R., Berger P.B. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005; 95(10): 1218–22. doi: 10.1016/j.amjcard.2005.01.049.

  6. Fuster V., Sweeny J.M. Aspirin. A historical and contemporary therapeutic overview. Circulation. 2011; 123(7): 768–78. doi: 10.1161/CIRCULATIONAHA.110.963843.

  7. Knuuti J., Wijns W., Saraste A. et al. 2019. Рекомендации ЕSC по диагностике и лечению хронического коронарного синдрома. Российский кардиологический журнал. 2020; 2: 119–182. [Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Rossiyskiy kardiologicheskiy zhurnal. 2020; 2: 119–182 (In Russ.)]. doi: http://dx.doi.org/10.15829/1560-4071-2020-2-3757.

  8. Рекомендации ЕОК/ЕОСХ по диагностике и лечению заболеваний периферических артерий 2017. Российский кардиологический журнал. 2018; 8: 164–221. [2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Rossiyskiy kardiologicheskiy zhurnal. 2018; 8: 164–221 (In Russ.)]. doi: http://dx.doi.org/10.15829/1560-4071-2018-8-164-221.

  9. Рекомендации ЕОК по ведению пациентов с острым инфарктом миокарда с подъемом сегмента ST 2017. Российский кардиологический журнал. 2018; 5: 103–158. [The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rossiyskiy kardiologicheskiy zhurnal. 2018; 5: 103–158 (In Russ.)]. doi: http://dx.doi.org/10.15829/1560-4071-2018-5-103-158.

  10. Двойная антитромбоцитарная терапия при ишемической болезни сердца: обновленная версия 2017. Российский кардиологический журнал. 2018; 8: 113–163. [Dual anti-plate therapy for ischemic heart disease: 2017 updated version. Rossiyskiy kardiologicheskiy zhurnal. 2018; 8: 113–163 (In Russ.)]. doi: http://dx.doi.org/10.15829/1560-4071-2018-8-113-163.

  11. Collet J.F., Thiele H., Barbato Е.E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020; ehaa575. doi: 10.1093/eurheartj/ehaa575.

  12. 2018 Guidelines for the Early Management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018; 49(3): 46–99. doi: 10.1161/str.0000000000000163.

  13. Стабильная ишемическая болезнь сердца. Рекомендации Российского кардиологического общества. 2020. ID КР 155/1. Доступ: http://cr.rosminzdrav.ru/#!/schema/133 (дата обращения – 11.11.2020). [Stable ischemic heart disease. Russian Society of Cardiology guidelines. 2020. ID КР 155/1. URL: http://cr.rosminzdrav.ru/#!/schema/133 (date of access – 11.11.2020) (In Russ.)].

  14. Острый коронарный синдром с подъемом сегмента ST. Рекомендации Российского кардиологического общества. 2020. ID КР 157/1. Доступ: http://cr.rosminzdrav.ru/#!/schema/135 (дата обращения – 11.11.2020). [ST-segment elevation acute coronary syndrome. Russian Society of Cardiology guidelines. 2020. ID КР 157/1. URL: http://cr.rosminzdrav.ru/#!/schema/135 (date of access – 11.11.2020) (In Russ.)].

  15. Острый коронарный синдром без подъема сегмента ST. Рекомендации Российского кардиологического общества. 2020. ID КР 154/1. Доступ: http://cr.rosminzdrav.ru/#!/schema/1016 (дата обращения – 11.11.2020). [Acute coronary syndrome without ST segment elevation. Russian Society of Cardiology guidelines. 2020. ID КР 154/1. URL: http://cr.rosminzdrav.ru/#!/schema/1016 (date of access – 11.11.2020) (In Russ.)].

  16. Hybiak J., Broniarek I., Kiryczynski G. et al. Aspirin and its pleiotropic application. Eur J Pharmacol. 2020; 866: 172762. doi: 10.1016/j.ejphar.2019.172762.

  17. Гусев Е.И., Коновалов А.Н. Неврология и нейрохирургия. Клинические рекомендации. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа. 2015; 424 с. [Gusev E.I., Konovalov A.N. Neurology and neurosurgery. Clinical guidelines. 2nd edition, revised and enlarged. Moscow: GEOTAR-Media. 2015; 424 p. (In Russ.)].

  18. Ишемический инсульт и транзиторная ишемическая атака у взрослых. Рекомендации Национальной ассоциации по борьбе с инсультом, Всероссийского общества неврологов, Ассоциации нейрохирургов России, Объединения нейроанестезиологов и нейрореаниматологов, Союза реабилитологов России. 2015. ID: КР171. Доступ: https://neurologic.ru/wp-content/uploads/2018/06/kr171.pdf (дата обращения – 11.11.2020). [Ischemic stroke and transient ischemic attack in adults. Guidelines of the National Association for Stroke Control, the All-Russian Society of Neurologists, the Association of Neurosurgeons of Russia, the Association of Neuroanesthesiologists and Neuroresuscitators, the Union of Rehabilitologists of Russia. 2015. ID: КР171. URL: https://neurologic.ru/wp-content/uploads/2018/06/kr171.pdf (date of access – 11.11.2020) (In Russ.)].

  19. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978; 299(2): 53–59. doi: 10.1056/NEJM197807132990201.

  20. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71–86. doi: 10.1136/bmj.324.7329.71.

  21. Rothwell P.M., Giles M.F., Chandratheva A. et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370(9596): 1432–42. doi: 10.1016/S0140-6736(07)61448-2.

  22. Rothwell P.M., Algra A., Chen Z. et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet. 2016; 388(10042): 365–75. doi: 10.1016/S0140-6736(16)30468-8.

  23. Chi N-F., Wen C-P., Liu C-H. et al. Comparison between aspirin and clopidogrel in secondary stroke prevention based on real-world data. J Am Heart Assoc. 2018; 7(19): e009856. doi: 10.1161/JAHA.118.009856.

  24. Vidyanti A.N., Chan L., Lin C.L. et al. Correction: Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. PLoS One. 2020; 15(4): e0232016. doi: 10.1371/journal.pone.0232016.

  25. Baigent C., Collins R., Appleby P. et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither: the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998; 316(7141): 1337–43. doi: 10.1136/bmj.316.7141.1337.

  26. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: the RISC Group. Lancet. 1990; 336 (8719): 827–30.

  27. Cairns J.A., Gent M., Singer J. et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985; 313(22): 1369–75. doi: 10.1056/NEJM198511283132201.

  28. Lewis H.D. Jr., Davis J.W., Archibald D.G. et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med. 1983; 309(7): 396–403. doi: 10.1056/NEJM198308183090703.

  29. Theroux P., Ouimet H., McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988; 319(17): 1105–11. doi: 10.1056/NEJM198810273191701.

  30. Antithrombotic Trialists’ (ATT) Collaboration; Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849–60. doi: 10.1016/S0140-6736(09)60503-1.

  31. Pasea L., Chung S-C., Pujades-Rodriguez M. et al. Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. BMC Med. 2019; 17(1): 206. doi: 10.1186/s12916-019-1438-y.

  32. Belcaro G., Nicolaides A.N., Ramaswami G. et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study). Atherosclerosis. 2001; 156(2): 379–87. doi: 10.1016/s0021-9150(00)00665-1.

  33. Giannopoulos A., Kakkos S., Abbott A. et al. Long-term mortality in patients with asymptomatic carotid stenosis: implications for statin therapy. Eur J Vasc Endovasc Surg. 2015; 50(5): 573–82. doi: 10.1016/j.ejvs.2015.06.115.

  34. Criqui M.H., Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015; 116(9): 1509–26. doi: 10.1161/CIRCRESAHA.116.303849.

  35. Eagle K.A., Kline-Rogers E., Goodman S.G. et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004; 117(2): 73–81. doi: 10.1016/j.amjmed.2003.12.041.

  36. Sud A., Kline-Rogers E.M., Eagle K.A. et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother. 2005; 39(11):1792–97. doi: 10.1345/aph.1G249.

  37. Kulkarni S.P., Alexander K.P., Lytle B. et al. Long-term adherence with cardiovascular drug regimens. Am Heart J. 2006; 151(1):185–91. doi: 10.1016/j.ahj.2005.02.038.

  38. Mostaza J.M., Lahoz C., Martin-Jadraque R. et al. PRESENAP Study. Factors associated with the discontinuation of evidence-based cardiovascular therapies in patients with stable coronary artery disease: a primary care perspective. Eur J Cardiovasc Prev Rehabil. 2009; 16(1): 34–38. doi: 10.1097/HJR.0b013e32831a47f3.

  39. Herlitz J., Tуth P.P., Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010; 10(2):125–41. doi: 10.2165/11318440-000000000-00000.

  40. Garcia Rodriguez L.A., Cea-Soriano L., Martin-Merino E., Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011; 343: d4094. doi: 10.1136/bmj.d4094.

  41. Garcia Rodriguez L.A., Cea Soriano L., Hill C., Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011; 76(8): 740–46. doi: 10.1212/WNL.0b013e31820d62b5.

  42. Oscarsson A., Gupta A., Fredrikson M. et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010; 104(3): 305–12. doi: 10.1093/bja/aeq003.

  43. Sung J.J., Lau J.Y., Ching J.Y. et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010; 152(1): 1–9. doi: 10.7326/0003-4819-152-1-201001050-00179.

  44. Devereaux P.J., Mrkobrada M., Sessler D.I. et al. POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014; 370(16): 1494–503. doi: 10.1056/NEJMoa1401105.

  45. Sundstrom J., Hedberg J., Thuresson M. et al. Low-dose aspirin discontinuation and risk of cardiovascular events: A Swedish nationwide, population-based cohort study. Circulation. 2017; 136(13): 1183–92. doi: 10.1161/CIRCULATIONAHA.117.028321.

  46. Ивашкин В.Т., Шептулин А.А., Маев И.В. с соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. РЖГГК онлайн. Доступ: http://www.gastro.ru/userfiles/R_npvp_2014_6.pdf (дата обращения – 11.11.2020). [Ivashkin V.T., Sheptulin A.A., Maev I.V. et al. Russian Gastroenterological Association clinical guidelines on diagnostics and treatment of NSAIDs-associated erosive and ulcerative lesions of the stomach and duodenum. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii (online version). URL: http://www.gastro.ru/userfiles/R_npvp_2014_6.pdf (date of access – 11.11.2020) (In Russ.)].

  47. Макарова Е.И., Толордава Г.А., Аринина Е.Е. Фармакоэкономический анализ лекарственного средства Тромбо АСС в лечении больных с перенесенными сердечно-сосудистыми событиями. Фармакоэкономика: теория и практика. 2015; 4: 69–80. [Makarova E.I., Tolordava G.A., Arinina E.E. Pharmacoeconomic analysis of Thrombo ASS in treatment of patients with previous cardiovascular events. Farmaekonomika: teoriya i praktika. 2015; 4: 69–80 (In Russ.)].


About the Autors

Alla B. Khadzegova, MD, professor of the Department of general therapy of Continuous professional education Faculty of N.I. Pirogov Russian scientific medical University of the Ministry of Healthcare of Russia, physician of functional diagnostics of City clinical hospital No 40 of Moscow Department of Healthcare. Address: 123182, Moscow, 3 Pekhotnaya str. Tel.: +7 (916) 550-40-52. E-mail: alla.h@mail.ru


Similar Articles

Back to Content

Бионика Медиа